News

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.

Takeda Pharmaceutical from Japan said on December 17, 2025, that its experimental pill for a type of skin disease, which is developed using artificial intelligence, has succeeded in two late-stage studies. Over half of the plaque psoriasis patients throughout the...

Egypt has gone on to mark quite a prominent milestone when it comes to its biopharmaceutical development by laying the foundation stone for the GENNVAX vaccine manufacturing facility, which is all set to become the largest fully integrated vaccine...

For a $950 million upfront, Sobi is all set to get rights to pozdeutinurad - oral URAT1 inhibitor that performed pretty well in the Phase II studies. Sobi is taking over Arthrosi Therapeutics, which is California-based, in a move to...

Bicycle Therapeutics has entered into a 15-year agreement with the UK Nuclear Decommissioning Authority (NDA) to utilize reprocessed uranium from nuclear reactors for the production of precision cancer therapies. Under the terms of the deal, announced by the UK government,...

On December 12, 2025, the U.S. health regulator went ahead and approved the oral antibiotic by Innoviva for treatment of gonorrhea, which is a common sexually transmitted infection, by way of offering patients an alternative to the injectable drug,...

In one of the most prominent developments for the biotech sector, BaseLaunch has officially welcomed Takeda as its new pharmaceutical partner. This collaboration is going to enhance the present partnership with five other leading pharma companies, now totaling six....